Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;28(10):1941-8.
doi: 10.1038/leu.2014.127. Epub 2014 Apr 3.

Mesenchymal stromal cells in the antimicrobial host response of hematopoietic stem cell recipients with graft-versus-host disease--friends or foes?

A Balan  1 , G Lucchini  2 , S Schmidt  2 , A Schneider  2 , L Tramsen  2 , S Kuçi  2 , R Meisel  3 , P Bader  2 , T Lehrnbecher  2
Affiliations
Review

Mesenchymal stromal cells in the antimicrobial host response of hematopoietic stem cell recipients with graft-versus-host disease--friends or foes?

A Balan et al. Leukemia. 2014 Oct.

Abstract

Mesenchymal stromal cells (MSCs) are multipotent cells, which exhibit broad immunosuppressive activities. Moreover, they may be administered irrespectively of human leukocyte antigen (HLA) compatibility, without inducing life-threatening immunological reactions, as they express no HLA class II and limited HLA class I antigens under resting conditions. These characteristics have made MSC an appealing candidate for cell therapy after hematopoietic stem cell transplantation (HSCT), for example, for treatment of graft-versus-host disease (GvHD) or for graft rejection prevention/treatment in allogeneic HSCT recipients. Unfortunately, information regarding the effect of MSC infusion on the host response to infectious agents is scarce, and study results on infectious complications in patients receiving MSC are conflicting. The present review focuses on the available data from in vitro studies and animal models regarding the interaction of MSC with bacterial, viral and fungal pathogens. In a clinical part, we present the current information on infectious complications in allogeneic HSCT recipients who had received MSCs as prophylaxis or treatment of GvHD disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bone Marrow Transplant. 2011 Feb;46(2):200-7 - PubMed
    1. Blood. 2008 Aug 1;112(3):532-41 - PubMed
    1. Int J Hematol. 2012 Dec;96(6):822-4 - PubMed
    1. Biochem Biophys Res Commun. 2007 Sep 28;361(3):745-50 - PubMed
    1. Exp Hematol. 2005 Aug;33(8):928-34 - PubMed

Publication types

MeSH terms